Interferon γ Induction of Pulmonary Emphysema in the Adult Murine Lung

By Zhongde Wang,* Tao Zheng,† Zhou Zhu,* Robert J. Homer,** Richard J. Riese,¶ Harold A. Chapman, Jr.,§ Steven D. Shapiro,** and Jack A. Elias*

From the *Department of Internal Medicine, Section of Pulmonary and Critical Care Medicine, and the †Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06520; the ¶Pathology and Laboratory Medicine Service, VA Connecticut Health Care System, West Haven, Connecticut 06516; ‡Harvard University, Boston, Massachusetts 02115; the §Cardiovascular Research Institute, University of California at San Francisco School of Medicine, San Francisco, California 94143; and the **Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri 63110

Abstract

Chronic inflammation containing CD8+ lymphocytes, neutrophils, and macrophages, and pulmonary emphysema coexist in lungs from patients with chronic obstructive pulmonary disease. Although this inflammatory response is believed to cause the remodeling that is seen in these tissues, the mechanism(s) by which inflammation causes emphysema have not been defined. Here we demonstrate that interferon γ (IFN-γ), a prominent product of CD8+ cells, causes emphysema with alveolar enlargement, enhanced lung volumes, enhanced pulmonary compliance, and macrophage- and neutrophil-rich inflammation when inducibly targeted, in a transgenic fashion, to the adult murine lung. Prominent protease and antiprotease alterations were also noted in these mice. They included the induction and activation of matrix metalloproteinase (MMP)-12 and cathepsins B, H, D, S, and L, the elaboration of MMP-9, and the selective inhibition of secretory leukocyte proteinase inhibitor. IFN-γ causes emphysema and alterations in pulmonary protease/antiprotease balance when expressed in pulmonary tissues.

Key words: chronic obstructive pulmonary disease • matrix metalloproteinase • cathepsin • neutrophil • secretory leukocyte proteinase inhibitor

Introduction

Chronic obstructive pulmonary disease (COPD) is a generic term covering several clinical syndromes including emphysema and chronic bronchitis. Chronic bronchitis is diagnosed in patients with a history of cough or sputum production on most days for at least 3 mo for two consecutive years without any other explanation (1, 2). In contrast, emphysema is defined pathologically as a condition of the lung characterized by abnormal permanent enlargement of the air spaces distal to the terminal bronchiole accompanied by destruction of alveolar walls (1, 2). COPD is a pressing clinical problem. In the USA, it affects over 16 million people, accounts for 13% of hospitalizations, and is the fourth leading cause of death (1, 3). In addition, 48 million people in the USA smoke cigarettes, the major cause of COPD, and 3,000 people, mostly teenagers, take up the habit each day (1). Worldwide, 1.5 million deaths per year due to COPD are predicted in China alone over the next half century (4). In contrast to its impressive health care importance, COPD is the least funded disease by the USA National Institutes of Health when adjusted for disease burden (5).

Tissue inflammation is noted throughout the bronchial tree and in the parenchyma of lungs from patients with COPD. Neutrophil-, macrophage-, and/or eosinophil-rich tissue and airway responses are seen in these locations (3, 6–11). Lymphocyte infiltration with the enhanced accumula-
tion of CD8\(^+\) cells is also a prominent finding (7–9, 11). It has long been assumed that this inflammation causes the tissue remodeling seen in COPD (1, 12, 13). However, the features of this inflammatory response that cause alveolar remodeling and the mediators that are responsible for these changes are poorly understood.

Several lines of evidence suggest that pulmonary lymphocytes contribute in important ways to the pathogenesis of the tissue remodeling responses in COPD. They include studies demonstrating correlations between lymphocyte counts and indices of alveolar destruction (14) and CD8\(^+\) cell numbers and the degree of COPD airflow limitation (8, 11). These lymphocytes are believed to be predominantly type 1 T cytotoxic (Tc1) cells that produce cytokines like IFN-\(\gamma\) (6, 11, 15). Surprisingly, the ability of the cytokines that are produced by these cells to generate the alterations seen in pulmonary emphysema have not been defined.

Studies of human \(\alpha\)-antitrypsin (\(\alpha\)-AT) deficiency and experiments with animal models of emphysema induced by papain or other proteases demonstrated that emphysema can be caused by proteolytic injury to the pulmonary matrix, particularly to elastin (1, 16). This led to the protease/antiprotease hypothesis, which is still the prevailing concept in the pathogenesis of emphysema. According to this hypothesis, the normal lung is protected by an “antiprotease shield” that neutralizes proteolytic enzymes that are released into the airway or parenchyma. Emphysema is caused by an alteration in this balance with an increase in proteases and/or a reduction in antiproteases (1, 3). Ineffective and/or disordered repair of elastic fibers and/or collagen- and oxidant-induced pulmonary injury may also contribute to the generation of these lesions (17–19). However, the ability of the inflammatory cells and mediators in COPD tissues to induce protease/antiprotease abnormalities that can contribute to, or activate, pulmonary proteolysis has not been adequately investigated.

In keeping with the belief that CD8\(^+\) Tc1 cells play an important role in the pathogenesis of emphysema, we hypothesized that IFN-\(\gamma\) could induce the alveolar destruction characteristic of this disorder. To test this hypothesis, we used an inducible overexpression transgenic modeling system to target IFN-\(\gamma\) to the adult murine lung. These studies demonstrate that IFN-\(\gamma\) causes a phenotype that mirrors human COPD with progressive emphysema, enhanced lung volumes, and macrophage and neutrophilic inflammation. They also define the prominent matrix metalloproteinase (MMP), cathepsin, and antiprotease alterations induced by IFN-\(\gamma\) in this in vivo setting.

**Materials and Methods**

**Transgenic Mice.** Mice and humans are born with premature lungs that contain large sac-like structures. Normal alveolar size and number are acquired only after a growth and septation process that occurs during the first month and years of life, respectively (20). Thus, enlarged alveoli in adult mice or humans can be caused by processes that alter alveolar development or processes that destroy otherwise normal alveolar septae (1, 21, 22). The emphysema in COPD is caused by the latter (1). Overexpression transgenic modeling in the lung uses either the clara cell 10-kD (CC10) or surfactant approtein C promoters most frequently. Both promoters are activated in utero and, when used to drive an appropriate transgene, have been shown to cause developmental abnormalities (22–24). The need to differentiate developmental- and adult onset phenotypes confounds the use of pulmonary overexpression transgenic modeling to study the pathogenesis of COPD. To avoid this confounder, we used a novel, externally regulatable, dual construct overexpression transgenic system developed in our laboratory (22). This transgenic system allows transgene expression to be minimized during phases of lung development and induced after lung development has occurred. The constructs used in this system have been described previously by our laboratory (22). The CC10-rtTA-hGH construct contains the CC10 promoter, the reverse tetracycline transactivator (rtTA), and human growth hormone (hGH) intronic and polyadenylation sequences (Fig. 1). The rtTA is a fusion protein made up of a mutated tetracycline repressor (rtet-R) and the herpes virus VP-16 transactivator. The tet-O-CMV-IFN-\(\gamma\)-hGH construct contains a polymeric tetracycline operator (tet-O), minimal CMV promoter, murine IFN-\(\gamma\) cDNA, and hGH intronic and polyadenylation signals (Fig. 1). In this system, the CC10 promoter directs the expression of rtTA to the lung. In the presence of doxycycline (dox), rtTA is able to bind in trans to the tet-O, and the VP-16 transactivator activates IFN-\(\gamma\) gene transcription. In the absence of dox, rtTA binding occurs at very low levels and only low level gene transcription is noted. The preparation of the CC10-rtTA construct has been described previously (22). The tet-O-CMV-IFN-\(\gamma\)-hGH construct was prepared by replacing the IL-11 cDNA in the construct tet-O-CMV-hil-11-hGH described previously by our laboratory (22) with the murine IFN-\(\gamma\) cDNA. This construct was checked for correct insert orientation by restriction enzyme digestion and sequencing. Both constructs were purified, linearized, separated by electrophoresis through agarose, and purified as described previously (22). Transgenic mice were prepared in (CBA \(\times\) C57BL/6)F\(_2\) eggs by mixing and simultaneously injecting the constructs into pronuclei as described previously (22).

**Documentation of Transgene Status.** The presence or absence of the transgenes was initially evaluated using Southern blot analysis and later by PCR. Southern analysis was performed as described previously using cDNA encoding murine IFN-\(\gamma\) or rtTA (22, 25). PCR for rtTA was also performed using protocols described previously (22).

![Figure 1](image.png)

**Figure 1.** Constructs used in the generation of CC10-rtTA-IFN-\(\gamma\) mice.
by our laboratory (22, 25). PCR for the IFN-γ–containing construct was undertaken using the following primers: upper primer 5'−ACT CAC ATT CAG AAC CCC AAA C−3', lower primer 5'−CGT CAG ATC GCC TGG AGA C−3'. The cycling conditions were one cycle at 94°C for 4 min, 35 cycles of 94°C for 1 min, followed by 57°C for 1 min and 72°C for 1 min, 1 cycle at 72°C for 5 min, and 1 cycle at 4°C to end. All CC10-rtTA-IFN-γ lineage animals were evaluated for the presence of both the rtTA- and IFN-γ–containing transgenic constructs.

**Dox Water Administration.** CC10-rtTA-IFN-γ animals were maintained on normal water until 4–6 wk of age. At that time they were randomized to receive normal water or water containing dox (1.0 mg/ml) as described previously (22).

**Bronchoalveolar Lavage and Quantification of IFN-γ Levels.** Mice were killed, the trachea was isolated by blunt dissection, and small caliber tubing was inserted and secured in the airway. Three volumes of 0.75 ml of PBS with 0.1% BSA were then installed and gently aspirated and pooled. Each bronchoalveolar lavage (BAL) fluid sample was centrifuged and the supernatants were stored at −70°C until used. The levels of IFN-γ were determined immunologically using a commercial ELISA (R&D Systems) as per the manufacturer’s instructions.

**Table I. RT-PCR Primers**

| mRNA of interest       | Sequences                        | Product length |
|------------------------|----------------------------------|----------------|
| Gelatinase A (MMP-2)   | (UP) 5′−TCT GGC GTG TCT CTG GTG C-3’ |                |
| Matrilysin (MMP-7)     | (UP) 5′−ACA TCA GTG GGA ACA GCC TCA G-3’ | 606 bp         |
| Gelatinase B (MMP-9)   | (UP) 5′−CAA AGA CCT GAA AAG GCC TCA G-3’ | 757 bp         |
| Macrophage metalloelastase (MMP-12) | (UP) 5′−AGA ACC CAT GCT CAG TCT CCA CTA C-3’ | 631 bp         |
| Collagenase (MMP-13)   | (UP) 5′−CTT CTG GCC GTG TCT TCT CCA CTA C-3’ | 606 bp         |
| MT-MMPI (MMP-14)       | (UP) 5′−CAT GCA CAG CCA CCA AGA AGA T-3’ | 690 bp         |
| TIMP-1                 | (UP) 5′−GCA TCT GCC AGT CTC TCT TGG C-3’ | 637 bp         |
| TIMP-2                 | (UP) 5′−GAC AGT CTT CAG GCT TCA GGA CTT TTT CCA TCA C-3’ | 598 bp         |
| TIMP-3                 | (UP) 5′−GCG ACC TCT GCT CAG TCT TCT CCA CTA C-3’ | 659 bp         |
| TIMP-4                 | (UP) 5′−GGA AGA AGG GCT TCG GAG TTC AGA A-3’ | 269 bp         |
| Cathepsin B            | (UP) 5′−GAA TGG TAG ACT CCA CTT GAA C-3’ | 513 bp         |
| Cathepsin L            | (UP) 5′−CTA CAC AAG GAA GAC TAC AAC A-3’ | 600 bp         |
| Cathepsin K            | (UP) 5′−AGA AGA CAT GAC CAG TGA AGA A-3’ | 481 bp         |
| Cathepsin H            | (UP) 5′−AGG TTC TTT TGG GGT GCC AAG CTT A-3’ | 595 bp         |
| Cathepsin S            | (UP) 5′−AGT AGG AGG CAT CAT A-3’ | 425 bp         |
| SLPI                   | (UP) 5′−ACT ACT GAC AGG AAT ACT A-3’ | 398 bp         |
| α1-AT                  | (UP) 5′−ACT TGG GCC TCT GAG TCT CTG A-3’ | 498 bp         |

UP, upper; LO, lower; MT-MMPI, membrane-type MMP1.
Lung Volume and Compliance Assessment. The animals were anesthetized, the trachea was cannulated, and the lungs were ventilated with 100% O2 via a “T” piece attachment. The tracheal cannula was then clamped and oxygen was absorbed in the face of ongoing pulmonary perfusion. At the end of this degassing, the lungs and heart were removed en bloc and inflated to 25 cm pressure with PBS. Static compliance was calculated as the change in volume divided by the change in pressure.

Histologic Analysis. Animals were killed, a median sternotomy was performed, and right heart perfusion was accomplished with calcium and magnesium–free PBS to clear the pulmonary intravascular space. The heart and lungs were then removed en bloc, inflated to 25 cm with neutral-buffered 10% formalin, fixed overnight in 10% formalin, embedded in paraffin, sectioned at 5 μm, and stained. Hematoxylin and eosin, Congo red, and periodic acid-Schiff with diastase (D-PAS) stains were performed in the Research Histology Laboratory of the Department of Pathology at Yale University School of Medicine.

mRNA Analysis. mRNA levels were assessed using Northern blot and reverse transcription (RT)-PCR as described previously by our laboratories (25, 26). In these experiments, total cellular RNA from lungs or a variety of other mouse tissues were obtained using Trizol reagent (GIBCO BRL) as per the manufacturer’s instructions. When Northern blots were being performed, the RNA was fractionated by formaldehyde–agarose gel electrophoresis, transferred to a nylon membrane, and probed with 32P-labeled cDNA encoding the moiety of interest. The cDNA probes were generated using RT-PCR with the primers in Table I and whole lung RNA from CC10–IL-13 mice (25). All cDNA was sequenced before utilization. Equity of sample loading and the efficacy of transfer were assessed by stripping and reprobing the membrane with cDNA encoding β-actin. In the RT-PCR assays, RNA samples were obtained and reverse transcribed. For the proteases and antiproteases, gene–specific primers (Table I) were used to amplify selected regions of each target moiety. When IFN-γ mRNA was being assessed, an upper primer in IFN-γ and a lower primer in hGH were used (upper GAGGAACCTGGGCAAAGGATG; lower GATTT-TAGGGGCCTACCT). This yielded a 418-bp reaction product. To verify that equal amounts of undegraded RNA were added in each RT-PCR reaction, β-actin was used as an internal standard. PCR products were quantitated after 20, 25, and 30 cycles of amplification. Amplified PCR products were detected using ethidium bromide gel electrophoresis, quantitated electronically, and confirmed by nucleotide sequencing.

Western Blot Analysis. Western blot analysis of BAL fluid was performed using antibodies to MMP-12 (27) as described previously by our laboratories (26). Activase Probe Analysis of Cysteine Proteases. Active site probe analyses were performed as described previously by our laboratories (29). Lung lysates or cell-free BAL, normalized to total protein, were incubated with an 125I-JPM analogue of E-64 and resolved by SDS-PAGE and autoradiography.

Morphometric Analysis. Alveolar size was estimated from the mean cord length of the airspace as described previously by our laboratories (30). This measurement is similar to the mean linear intercept, a standard measure of air space size, but has the advantage that it is independent of alveolar septal thickness. Sections were prepared as described above. To obtain images at random for analysis, each glass slide was placed on a printed rectangular grid and a series of dots was placed on the coverglass at the intersection of the grid lines, i.e., at ~1-mm intervals. Fields as close as possible to each dot were acquired by systematically scanning at 2-mm intervals. Fields containing identifiable artifacts or non-alveolated structures such as bronchovascular bundles or pleura were discarded.

A minimum of 10 fields from each mouse lung were acquired into a Macintosh computer through a framegrabber board. Images were acquired in 8 bit grayscale at a final magnification of 1.5 pixels/μm. The images were analyzed on a Macintosh G3 computer using the public domain NIH Image program written by Wayne Rasband at the National Institutes of Health (available at http://rsb.info.nih.gov/nih-image using a custom written macro available from the web site). Images were manually thresholded, then smoothed and inverted. The image was then subject to sequential logical image match “and” operations with a horizontal and then vertical grid. At least 200 measurements per field were made in transgene-positive animals and 400 measurements per field were made in the transgene-negative animals. The length of the lines overlying air space was averaged as the mean chord length. At least four animals were studied at each time point in the presence and absence of dox water. Chord length increases with alveolar enlargement.

Statistical Analysis and Data Presentation. Values are expressed as means ± SEM. As appropriate, group means were compared by analysis of variance with Scheffe’s procedure post hoc analysis or with the Student’s two-tailed unpaired t test using the StatView software for the Macintosh (Abacus Concepts, Inc.). The illustrated effects of IFN-γ on the levels of mRNA encoding proteases or antiproteases are representative of the results obtained in evaluations of a minimum of six separate animals.

Results

Generation of Transgenic Mice. To characterize the effects of IFN-γ in the adult lung, we used a novel, externally regulatable, dual construct overexpression transgenic system developed in our laboratory (22). The constructs required for these transgenics were prepared, purified, and simultaneously microinjected. Tail biopsies were obtained and

Figure 2. Southern blot analysis of DNA from potential founder mice. The requisite constructs were prepared and microinjected as described in Materials and Methods. Tail biopsies were obtained from potential founder animals. DNA was extracted, and the presence of the rtTA- and IFN-γ-containing constructs was evaluated by Southern blot analysis. The transgenes in three dual transgene-positive founder mice and a transgene-negative littermate control are compared with copy number controls of the CC10–rtTA-hGH and tet-O-CMV-IFN-γ-hGH constructs.
from potential founder animals, DNA was isolated, and the presence or absence of the IFN-γ and rtTA transgenic sequences was determined via Southern blot analysis and PCR. Three dual-positive founder animals were obtained (Fig. 2). They were subsequently backcrossed with C57BL/6 mice to generate transgene-negative and transgene-positive progeny.

**Regulation of IFN-γ Production.** Transgene-negative and transgene-positive mice were kept on normal water until they were 4–6 wk of age. They were then randomized to normal water or water with dox. In the absence of dox administration, BAL IFN-γ levels were <70 pg/ml. As illustrated in Fig. 3, dox administration caused a significant increase in BAL IFN-γ. This increase was noted within 24 h of dox administration, persisted for extended intervals, and returned to baseline values within 4 d of removing the dox from the animal’s drinking water. The different transgenic lines had BAL IFN-γ levels between 370 and 1,200 pg/ml after 1 wk of dox administration.

To determine if the IFN-γ that was produced in our transgenic animals was bioactive, studies were undertaken to determine if the IFN-γ-regulated genes IFN-γ-inducible protein 10 (IP-10) and monokine induced by IFN-γ (Mig) were stimulated after dox administration. mRNA encoding either gene could not be appreciated in transgene-negative mice on normal water or dox water (Fig. 4). In contrast, mRNA encoding IP-10 and Mig was weakly detected in transgene-positive mice on normal water, and impressive induction of both genes could be appreciated after dox administration (Fig. 4). These studies clearly demonstrate that the IFN-γ that is produced in the lungs of these transgenic mice is bioactive.

**Organ Specificity of Transgene Expression.** To determine if IFN-γ was appropriately targeted to the lung, RNA was obtained from the lungs and a variety of other tissues from...
transgene-positive mice that had received dox water for 2 wk. IFN-γ mRNA was then evaluated via RT-PCR analysis. Impressive levels of IFN-γ mRNA could be appreciated in lungs from transgene-positive mice on dox water. In contrast, transgene-induced IFN-γ mRNA was not noted and histologic abnormalities were not appreciated in a variety of visceral tissues from transgene-positive animals (Fig. 5, and data not shown). This demonstrates that our CC10-driven transgenic system, as described previously by this laboratory and others (22, 23, 31), selectively targets IFN-γ to the lungs of these transgenic animals.

**Table II. IFN-γ Regulation of BAL Cellularity**

| Transgene status | Recovery | M   | L   | N   | E   |
|------------------|----------|-----|-----|-----|-----|
| ±                | ×10⁶     | %   | %   | %   | %   |
| - dox            | 4.2 ± 0.6| 97 ± 0.6| 2.2 ± 0.4| 0.4 ± 0.3| 0.3 ± 0.2|
| + dox            | 10 ± 4.3 | 56 ± 5.1| 28 ± 5.0| 15 ± 3.0| 1 ± 0.1|
| + dox            | 38.1 ± 7.8| 54 ± 3.6| 31 ± 3.5| 15 ± 1.7| 0.1 ± 0.01|

*4–6-wk-old transgene-negative (−) and dual transgene-positive (+) mice were placed on normal water (−dox) or dox water (+dox) for 1 mo. BAL was then performed and cell recovery and differentials were evaluated. The noted values represent the mean ± SEM of a minimum of three animals.

‡P < 0.01 versus transgene-negative mice and transgene-positive mice on normal water.

§P < 0.05 versus transgene-negative mice.

**Effect of IFN-γ on BAL Cellularity.** Dual transgene-positive and transgene-negative mice were kept on normal water until they were 4–6 wk of age. They were then placed on normal water or water with dox and maintained on this regimen for an additional month. At the end of this interval they were killed and BAL cellularity was evaluated. The cell recovery and cellular differentials of BAL fluids from transgene-negative mice on normal and dox water were almost identical (Table II). In contrast, IFN-γ increased BAL cell recovery. Modest increases in cellularity were seen in transgene-positive mice on normal water and impressive increases were seen after dox induction. At this time point, BAL fluids from dual transgene-positive mice on dox water had ~9- and 11.5-fold more cells than the BAL fluids from transgene-negative animals on normal and dox water, respectively (Table II; P < 0.005). The BAL fluids from the transgene-positive mice also had an increased percentage and recovery of neutrophils and lymphocytes and an exaggerated number of macrophages compared with transgene-negative controls (P < 0.05 for all comparisons; Table II). Abnormalities in eosinophil recovery were not noted. These studies demonstrate that IFN-γ increases the pulmonary accumulation of macrophages, lymphocytes, and neutrophils.

**Histologic, Physiologic, and Structural Effects of IFN-γ.** Inflammation and mucus metaplasia were not seen in the hematoxylin and eosin and periodic acid–Schiff stains of the lungs from transgene-negative mice on normal water. Similarly, mucus alterations were not noted in the histologic sections from the transgene-positive mice on normal or dox water (data not shown). In contrast, inflammation was noted in lungs from transgene-positive animals. This re-

**Figure 6. Inflammation in transgenic mice.** Transgene-negative, Tg (−), and dual transgene-positive, Tg (+), mice at 1 mo of age were randomized to normal water, dox (−), or dox water, dox (+), for 3 mo. The lungs were then removed, fixed to pressure, sectioned, stained (hematoxylin and eosin), and photographed (original magnification: ×100). These photomicrographs are representative of the results obtained in a minimum of 10 experiments evaluating the histology of transgene-positive and transgene-negative mice on normal water or dox water.
sponse contained increased numbers of mononuclear cells and rare neutrophils. It was mild and patchy and, when seen, was noted in peribronchiolar and alveolar parenchymal locations. Abnormalities of the airways in these locations were not appreciated. This response could be appreciated in transgene-positive mice that had received at least 1 mo of dox water but was not consistently detected in transgene-positive mice on normal water (Fig. 6, and data not shown).

The alveoli in lungs from transgene-negative mice on normal water and dox water were normal in size and appearance (Fig. 7). In contrast, alveolar enlargement was noted in the dual transgene-positive animals. A modest increase in alveolar size was seen in 1-mo-old, dual transgene-positive mice that had received normal water (Fig. 7). Dox-induced IFN-γ caused a further increase in alveolar size. This effect was dose and time dependent. It was most prominent in transgenic lines that produced high levels of IFN-γ after dox administration. In these mice, a marginal increase in alveolar size was noted after 4–6 wk and impressive emphysema was noted after 3 mo of dox administration (Fig. 7, and data not shown). This emphysema manifest as histologic (Fig. 7) and morphometrically obvious (Fig. 8) alveolar enlargement with loss of the orderly appearance of the acinus (32). The morphometric studies revealed a >100% increase in chord length. This is signifi-

**Figure 7.** Alveolar histology in transgenic mice. Transgene-negative, Tg (−), and dual transgene-positive, Tg (+), mice at 1 mo of age were randomized to normal water, dox (−), or dox water, dox (+), for 3 mo. The lungs were then removed, fixed to pressure, sectioned, stained (hematoxylin and eosin), and photographed (original magnification: ×25). Mild alveolar enlargement is seen in the transgene-positive animals on normal water and further alveolar enlargement is seen in transgene-positive animals receiving dox. These photomicrographs are representative of the results obtained in a minimum of 10 experiments evaluating the alveolar histology of transgene-positive and transgene-negative mice on normal water and dox water.

**Table III.** Effects of IFN-γ on Lung Volume and Static Compliance

| Transgene status* | Dox | Lung volume | Compliance |
|-------------------|-----|-------------|------------|
|                   | ml  | ml/cm       |            |
| Neg                | −   | 0.9 ± 0.001 | 0.036 ± 0.001 |
| Pos                | −   | 0.9 ± 0.04  | 0.036 ± 0.003 |
| Neg                | +   | 1.5 ± 0.13  | 0.06 ± 0.001 |
| Pos                | +   | 2.4 ± 0.04* | 0.096 ± 0.05* |

*1-mo-old transgene-negative (−) and dual transgene-positive (+) mice were randomized to normal water or dox water for 3 mo. Lung volumes were then assessed via volume displacement after fixation to pressure (25 cm). The noted values represent the mean ± SEM of evaluations on a minimum of four mice for each group.

†P < 0.05 versus transgene-positive mice on normal water and transgene-negative mice on normal or dox water.

*Figure 8.** Morphometric parameters of alveolar size in CC10-rtTA-IFN-γ mice. Transgene-negative (Neg) and transgene-positive (Pos) mice were randomized to normal water (−Dox) or dox water (+Dox) at 1 mo of age and maintained on this regimen for 3 mo. Lungs were then removed, fixed to pressure, stained, and alveolar chord length was quantitated (*P < 0.01 versus all other conditions). The noted values represent the mean ± SEM of a minimum of five animals.
Interferon-γ (IFN-γ) and doxycycline (Dox) treatment significantly greater than the 25–30% increase in morphometric parameters of alveolar size that we noted in similar mice exposed to cigarette smoke for 6 mo (27).

Enhanced lung volumes and increased pulmonary compliance are characteristic features of human emphysema (1). To determine if this murine model recapitulates these important clinical features of COPD, 1-mo-old transgene-negative and transgene-positive mice were randomized to normal water and dox water for up to 3 mo. Lung volumes were then assessed after pressure fixation. As can be seen in Table III and Fig. 9, dox induction of IFN-γ caused a progressive increase in lung volume and an impressive increase in pulmonary compliance compared with dual transgene-positive animals on normal water or transgene-negative animals on normal or dox water. When viewed in combination, these studies demonstrate that IFN-γ causes emphysema with lung volume enlargement and enhanced pulmonary compliance analogous to that seen in human COPD.

Effect of IFN-γ on MMPs. To begin to define the mechanism(s) of IFN-γ–induced alveolar septal destruction, we compared the levels of mRNA encoding a variety of COPD-relevant MMPs in transgene-negative and transgene-positive mice that had been randomized to receive normal water or dox water at 1 mo of age and maintained on this regimen for up to 12 wk. These studies demonstrated that IFN-γ is a potent stimulator of MMP-12 mRNA accumulation (Fig. 10). This effect could be appreciated after as little as 1 wk of dox administration and was readily apparent throughout the 3-mo induction interval (data now shown). MMP-2, MMP-9, and MMP-14 mRNA were not induced in these animals. Western blot analysis confirmed the induction of MMP-12 (Fig. 11). Zymography also demonstrated IFN-γ–induced BAL moieties that comigrated with the unprocessed and/or fully processed forms of MMP-12 (Fig. 11). Interestingly, BAL moieties that comigrated with MMP-9 moieties were also appreciated (Fig. 11). The activities in these bands were in-
inhibited by EDTA, which establishes them as metalloproteinases. Thus, IFN-γ is a potent and selective inducer of MMP-12 and stimulates the release of MMP-9 in vivo.

**IFN-γ Regulation of Cysteine Proteinases.** Studies were next undertaken to determine if cysteine proteinases were induced by IFN-γ in our transgenic system. This was done by comparing the levels of mRNA encoding a variety of airway-relevant cysteine proteinases in lungs from dual transgene-positive animals and transgene-negative littermate controls that had been randomized to normal water or dox water at 1 mo of age and maintained on this regimen for 4 wk. RT-PCR and Northern blot evaluations demonstrated that IFN-γ increased the levels of mRNA encoding cathepsins D, H, S, and B. Stimulation of mRNA encoding cathepsins K and L could not be appreciated (Fig. 12, and data not shown). Active site probe analysis, which identifies bioactive cathepsin moieties (29), also demonstrated increased levels of cathepsins H, S, B, and L in lung lysates and free cathepsin B and S in BAL fluids (Fig. 13, and data not shown). Thus, IFN-γ is a potent in vivo inducer of cysteine proteinases in the lung.

**Figure 12.** Effect of IFN-γ on respiratory cathepsin mRNA. RT-PCR analysis was used to compare the levels of mRNA encoding the noted cathepsins in lung lysates from 2-mo-old transgene (Tg)-negative and transgene-positive CC10-rtTA-IFN-γ mice that had received normal water or dox water for the 4-wk interval before evaluation.

**Figure 13.** Effect of IFN-γ on cathepsin proteins (B, H, S, and L). 1-mo-old transgene-negative and dual transgene-positive mice were randomized to normal water or dox water. 4 wk later, active site probe analysis was used to characterize the levels of cathepsins in lysates from the lungs of these animals.

**IFN-γ Regulation of Antiproteases in the Lung.** To fully understand the protease/antiprotease balance in the lungs of IFN-γ transgenic mice, the levels of expression of lung-relevant antiproteases were also evaluated. Studies using RT-PCR and Northern blot analysis demonstrated that IFN-γ did not alter the expression of tissue inhibitor of metalloproteinase (TIMP)-1, TIMP-2, TIMP-3, or α1-AT. However, IFN-γ did significantly inhibit the expression of secretory leukocyte protease inhibitor (SLPI; Fig. 14, and data not shown).

**Figure 14.** Effect of IFN-γ on respiratory antiproteases. RT-PCR was used to compare the levels of mRNA encoding respiratory-relevant antiproteases in 2-mo-old transgene-negative and transgene-positive CC10-rtTA-IFN-γ mice that received either normal water (−) or dox water (+) from 1–2 mo of age. The lack of effect of IFN-γ on TIMP-1, -2, and -3, and α1-AT, and the ability of IFN-γ to inhibit SLPI can be appreciated.

**Discussion**

Chronic inflammation and structural remodeling coexist and are believed to be linked in a cause and effect fashion in COPD tissues (7, 12–14). Surprisingly, virtually nothing is known about the mechanism(s) by which COPD inflammation causes these structural alterations. We hypothesized that selected mediators of COPD tissue inflammation could directly induce pulmonary emphysema. To test this hypothesis, we used inducible overexpression transgenic modeling to target COPD-relevant inflammatory mediators to the adult murine lung. IFN-γ was chosen for these investigations. This choice was based on prior studies demonstrating that CD8+ lymphocyte infiltration is a prominent feature of the pathology of COPD, that lymphocytic number correlates with tissue destruction and airflow limitation in this disorder, and that CD8+ cells are potent producers of IFN-γ, and the belief that these cells elaborate type I cytokines (6–8, 11, 14, 15). These studies demonstrate that the overexpression of IFN-γ causes a phenotype that mirrors human COPD with prominent emphysema, enlarged lungs, enhanced pulmonary compliance, and a mixed tissue and BAL inflammatory response containing increased numbers of macrophages, lymphocytes, and neutrophils. They also demonstrate that IFN-γ shifts pulmonary protease/antiprotease balance in a proteolytic direction via inducing MMP-12 and a variety of cathepsins.
while inhibiting SLPI. These are the first studies to demonstrate that IFN-γ, or any type 1 cytokine, can cause COPD-relevant pulmonary structural remodeling and tissue inflammation. They are also the first studies to define the in vivo, protease/antiprotease alterations induced by IFN-γ in the lung. When viewed in combination, these studies demonstrate that IFN-γ is an important regulator of pulmonary protease/antiprotease balance and suggest that IFN-γ, and/or the pathways it activates, may contribute to the pathogenesis of pulmonary emphysema.

The type of immune response that develops in response to a foreign antigen can be attributed, at least in part, to the heterogeneity of responding T cell populations (33). Type I and type II polarized inflammatory responses represent contrasting and, at times, mutually antagonistic, responses of an organism to immunogenic insult. The specialized cytokine profiles of type 1 and type 2 lymphocytes that mediate these responses (for a review, see reference 34) are major determinants of the outcomes of many immune responses including autoimmune, allergic, and infectious diseases. This is nicely illustrated in our current concept of asthma pathogenesis, which suggests that CD4+ Th2-dominated inflammation is the cornerstone of this disorder (34). In contrast to asthma, CD8+ cells are the major lymphocytes in tissues from patients with COPD with airflow obstruction (8, 11). Until recently, CD8+ cells were considered a uniform class whose major function was MHC class I–restricted (cytotoxic) lysis of infected or altered host cells, at least in part, via the production of IFN-γ (11). It is now known that excessive or inappropriate activation of CD8+ cells can also induce pathologic changes in lung tissues (35) and that CD8+ cells have a broader cytokine profile than suspected previously (36). Our studies demonstrate that IFN-γ causes emphysema while inducing and activating a variety of pulmonary proteolytic pathways. This observation suggests that emphysema may be a Tc1/IFN-γ-mediated disorder. However, this speculation must be viewed with caution because sputum and tissue eosinophilia are also seen in some patients with this disorder (10, 37). This raises the possibility that type 2 cytokine mediators may also contribute to disease pathogenesis in some individuals. IL-13 is an attractive candidate mediator of this response because it induces tissue eosinophilia (25) and causes emphysema when targeted to the adult murine lung (37a). Interestingly, IL-13 can be produced by Tc1 as well as Tc2 cells (38). Thus, COPD, in these individuals, could be a mixed Tc1/Tc2 disorder or a Tc1-dominant disease in which IL-13 is produced and tissue eosinophilia is generated by Tc1 cells. These observations and our studies allow us, for the first time, to begin to view the spectrum of clinical presentations of COPD from the perspective of the Tc1/Tc2 cytokine paradigm. However, additional experimentation will be required to define the applicability of this paradigm to this complex disorder(s).

The recruitment and activation of neutrophils in the lung has been considered for years to be a major contributor to the pathogenesis of emphysema (16, 39). This is based on studies demonstrating neutrophil accumulation in BAL fluids and, to a lesser extent, tissues from patients with COPD (1, 6, 7, 16), correlations between neutrophil number and airflow obstruction in severe COPD (7), and the potent tissue-destructive and mucus-enhancing effects of neutrophil–derived serine proteases (13, 40, 41). Macrophage-derived leukotriene (LT)B4 (42), epithelial-derived IL-8 (16, 43), and cigarette-derived nicotine (44) have been postulated to contribute to the generation of neutrophilia in COPD. Repetitive endotoxin exposure has also been shown to produce pulmonary neutrophilia and emphysema in some animal modeling systems (45). Our studies demonstrate that the targeted pulmonary expression of IFN-γ increases BAL neutrophils to levels comparable to those seen in human COPD. Several laboratories have demonstrated that tissue neutrophilia can be induced in the lung via the passive transfer and activation of polarized type I cells (46) and that IFN-γ augments tissue responses to endotoxin (47). These findings suggest that CD8+ cell IFN-γ is responsible, at least in part, for the recruitment and activation of neutrophils in the lungs of cigarette smokers and that the structural events that ensue are mediated, in part, by the consequences of these cells in alveolar structures. They also raise the possibility that IFN-γ–induced exaggerated responses to ambient levels of environmental endotoxin may contribute to this response. These hypotheses link, for the first time, the lymphocyte and neutrophil abnormalities in COPD.

To gain insight into the mechanisms of IFN-γ–induced pulmonary proteolysis, we determined if IFN-γ altered the levels of expression of lung-relevant MMPs. These studies demonstrate, for the first time, that IFN-γ is a potent and selective stimulator of MMP-12 in vivo. This observation compliments prior studies from our laboratories that demonstrated that MMP-12 is essential for cigarette smoke–induced inflammation and emphysema in the murine lung (27) and is expressed in an exaggerated fashion in alveolar macrophages from smokers and patients with emphysema (48). Our studies also demonstrate, for the first time, that IFN-γ stimulates BAL MMP-9 protein accumulation and that these protein alterations are not associated with simultaneous increases in MMP-9 mRNA. The dissociation between the effects of IFN-γ on mRNA and protein suggests that IFN-γ increases MMP-9 elaboration by acting on cells with pools of preformed enzyme such as the neutrophil (49). In accord with these observations, exaggerated levels of MMP-9 have been found in BAL fluids from patients with COPD and the neutrophil has been shown to be the major source of this enzyme in this setting (50). When viewed in combination, these observations suggest that cigarette smoke may induce MMP-12 and stimulate MMP-9 elaboration via the induction of IFN-γ and that the ability of these MMPs to degrade elastin, basement membrane components (fibronectin, laminin, entactin, vitronectin, and type IV collagen), and nonbasement membrane components (converting plasminogen to angiostatin and activating latent TNF [17, 51]) contributes to the pathogenesis of IFN-γ–mediated lesions. However, it is important to point out that induction and exaggerated expression of the
and/or CD 8

portant to point out that exaggerated IFN-

comparable with human emphysema. However, it is im-

mations in TIMP-1, -2, and -3 and

lungs of IFN-

expression of a variety of important antiproteases in the

vanced sarcoidosis.

culosis and pulmonary inflammatory disorders such as ad-

remodeling, including pulmonary infections such as tuber-

nated tissue inflammation and tissue destruction or

portant in diseases characterized by type 1 cytokine–domi-

nary proteolytic responses. This could be particularly im-

portant in the pathogenesis of pulmonary emphysema and provide

lagenolytic, and gelatin degrading properties of these en-

zymes make them tempting candidates for the proteolysis that is believed to underlie pulmonary emphysema. They also raise the possibility that IFN-

or the proteolytic pathways it activates, plays important roles in other pulmo-

nary proteolytic responses. This could be particularly im-

portant in diseases characterized by type 1 cytokine–domi-

nated tissue inflammation and tissue destruction or remodeling, including pulmonary infections such as tuberculo-

sulosis and pulmonary inflammatory disorders such as advanced sarco-

dosis.

To fully understand the protease/antiprotease alterations that lead to emphysema, we also characterized the levels of expression of a variety of important antiproteases in the lungs of IFN-

overexpressing animals. Significant alter-

ations in TIMP-1, -2, -3 and \( \alpha_1 \)-AT were not noted. Interestingly, significant inhibition of SLPI was readily appreciated. SLPI is a 12-kD protein produced at epithelial surfaces. It is a potent inhibitor of elastase and serine prote-

inases, modulates tissue inflammation, and functions as a defensin–like antibiotic (56). It is thus reasonable to speculate that IFN-

inhibition of pulmonary SLPI can contrib-

ute to the proteolysis, chronic inflammation, and recurrent infections that are seen in patients with COPD.

Our studies demonstrate that the transgenic overexpres-

sion of IFN-

in the adult murine lung causes a phenotype compatible with human emphysema. However, it is impor-
tant to point out that exaggerated IFN-

production and/or CD 8* cell accumulation are also noted in a variety of other pulmonary disorders, including sarcoidosis, tuberculo-
sis, obliterative bronchiolitis, allograft rejection, pulmo-
nary fibrosis, and HIV and other viral infections (57–65). In accord with our hypothesis that chronic IFN-

production activates pulmonary proteolytic pathways, em-

physema is seen in patients with HIV infection (64) and pulmonary cavitation is seen in patients with advanced tu-

berculosis and sarcoidosis. The lack of emphysema or overt

pulmonary destruction in the other disorders may be due to differences in the site(s), timing, and/or magnitude of IFN-

production in the different disorders. Alternatively, it is well known that cytokine effector functions are context dependent with the same cytokine having different effects in different organs and different effects in the same organ, depending on the other cells and or mediators that are present in the local microenvironment. In addition, it is increasingly appreciated that host genetic background and polymorphisms in crucial disease-modifying genes also regu-

late the phenotypic features that are induced by inflamma-
tion-regulating mediators. Thus, as yet unidentified fea-
tures of the responses in these disorders may also serve to exaggerate or inhibit IFN-\( \gamma \)-induced pulmonary proteoly-

sis. Additional investigation will be required to define the conditions under which IFN-\( \gamma \) induces emphysema and pulmonary proteolysis and the responses that augment and/or ameliorate these responses.

In summary, these studies demonstrate that the targeted expression of IFN-\( \gamma \) in the adult lung causes emphysema and a macrophage–, lymphocyte–, and neutrophil-rich response that mirrors, in many ways, the lesions seen in hu-

man COPD. They also demonstrate that this emphysema-
tous response is associated with the induction and activation of MMP-12 and cathepsins B, H, S, D, and L, the enhanced elaboration of MMP-9, and the inhibition of SLPI. They suggest that IFN-\( \gamma \) may play an important role in the pathogenesis of pulmonary emphysema and provide the rationale for investigations of the role(s) of IFN-\( \gamma \) in the pathogenesis of human COPD.

The authors thank Kathleen Bertier for excellent secretarial and ad-

ministrative assistance.

This work was supported by National Institutes of Health grants HL56389, HL61904, and HL64242 (J.A. Elias), National Institutes of Health grant K08-AI01555 and a research grant from the American Lung Association (R. Riese), and National Institutes of Health grants HL50472 (S. Shapiro) and HL48261 (H. Chapman).

Submitted: 14 August 2000
Revised: 12 October 2000
Accepted: 17 October 2000

References

1. Senior, R.M., and S.D. Shapiro. 1998. Chronic obstructive pulmonary disease: epidemiology, pathophysiology, and pathogenesis. In Fishman’s Pulmonary Diseases and Disorders. Vol. I. A.P. Fishman, J.A. Elias, J.A. Fishman, M.A. Grippi, L.R. Kaiser, and R.M. Senior, editors. McGraw-Hill Inc., New York. 659–681.
2. American Thoracic Society. 1995. Definitions, epidemiology, pathophysiology, diagnosis, and staging. Am. J. Respir. Crit. Care Med. 152:S78–S83.
3. Jeffery, P.K. 1999. Inflammation in chronic obstructive lung disease. Am. J. Respir. Crit. Care Med. 160:S3–S14.
4. Petro, R., Z.M. Chen, and J. Boreham. 1999. Tobacco: the growing epidemic. Nat. Med. 5:15–17.
5. Gross, C.P., G.F. Anderson, and N.R. Powe. 1999. The relation between funding by the National Institutes of Health
and the burden of disease. N. Engl. J. Med. 340:1881–1887.
6. Cosio, M.G., and A. Guerassimov. 1999. Chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 160: S21–S25.
7. Saetta, M. 1999. Airway inflammation in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 160:517–520.
8. Saetta, M., S. Baraldo, L. Corbino, G. Turato, F. Braccioni, F. Rea, G. Cavallesco, G. Tropeano, C.E. Mapp, P. Maestrelli, et al. 1999. CD8+ve cells in the lungs of smokers with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 160:711–717.
9. Saetta, M., A. Di Stefano, P. Maestrelli, A. Ferrareoso, R. Drigo, A. Potena, A. Ciaccia, and L.M. Fabbri. 1993. Activated T-lymphocytes and macrophages in bronchial mucosa of subjects with chronic bronchitis. Am. Rev. Respir. Dis. 147:301–306.
10. Saetta, M., A. Di Stefano, P. Maestrelli, G. Turato, M.P. Ruggieri, A. Roggeri, P. Calcagni, C.E. Mapp, A. Ciaccia, and L.M. Fabbri. 1994. Airway eosinophilia in chronic bronchitis during exacerbations. Am. J. Respir. Crit. Care Med. 150:1646–1652.
11. O'Shaughnessy, T.C., T.W. Ansari, N.C. Barnes, and P.K. Jeffrey. 1997. Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T lymphocytes with FEV1. Am. J. Respir. Crit. Care Med. 158:852–857.
12. Senior, R.M. 2000. Mechanisms of COPD: conference summary. Chest 117(Suppl. 1):320S–323S.
13. Jeffrey, P.K. 2000. Comparison of the structural and inflammatory features of COPD and asthma. Chest 117(Suppl. 1):251S–260S.
14. Finkelstein, R., B.S. Fraser, H. Ghezzo, and M.G. Cosio. 1995. Alveolar inflammation and its relation to emphysema in smokers. Am. J. Respir. Crit. Care Med. 152:1666–1672.
15. Boushey, H.A. 1999. Glucocorticoid therapy for chronic obstructive pulmonary disease. N. Engl. J. Med. 340:1990–1991.
16. Stockley, R.A. 1999. Neutrophils and elastase/antiprotease imbalance. Am. J. Respir. Crit. Care Med. 160:S49–S52.
17. Shapiro, S.D. 1999. The macrophage in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 160:S29–S32.
18. Wright, J.L., and A. Churg. 1995. Smoke-induced emphysema in guinea pigs is associated with morphometric evidence of collagen breakdown and repair. Am. J. Physiol. 268:L17–L20.
19. MacNee, W., and I. Rahman. 1999. Oxidants and antioxidants as therapeutic targets in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 160:S58–S65.
20. Burri, P.H. 1997. Structural aspects of prenatal and postnatal development and growth of the lung. In Lung Growth and Development. Vol. 100. J.A. McDonald, editor. Marcel Dekker, Inc., New York. 1–35.
21. Snider, G.L., E.C. Lucey, and P.J. Stone. 1994. Pitfalls in antiprotease therapy of emphysema. Am. J. Respir. Crit. Care Med. 150:S131–S137.
22. Ray, P., W. Tang, P. Wang, R. Homer, C.I. Kuhn, R.A. Flavell, and J.A. Elias. 1997. Regulated overexpression of interleukin-11 in the lung: use to dissociate development-dependent and -independent phenotypes. J. Clin. Invest. 100:2501–2511.
23. Tang, W., G.P. Geba, T. Zheng, P. Ray, R. Homer, C. Kuhn, R.A. Flavell, and J.A. Elias. 1996. Targeted expression of IL-11 in the murine airway causes airways obstruction, bronchial remodeling and lymphocytic inflammation. J. Clin. Invest. 98:2845–2853.
24. Zhou, L., C.R. Dey, S.E. Wert, and J.A. Whitsett. 1996. Arrested lung morphogenesis in transgenic mice bearing an SP-C-TGF-β1 chimeric gene. Dev. Biol. 175:227–238.
25. Zhu, Z., R.J. Homer, Z. Wang, Q. Chen, G.P. Geba, J. Wang, Y. Zhang, and J.A. Elias. 1999. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities and ecoxin production. J. Clin. Invest. 103:779–788.
26. Yoon, H.J., Z. Zhu, J.M. Gwaltney, Jr., and J.A. Elias. 1999. Rhinovirus regulation of IL-1 receptor antagonist in vivo and in vitro: a potential mechanism of disease resolution. J. Immunol. 162:7461–7469.
27. Houtamaki, R.D., D.K. Kobayashi, R.M. Senior, and S.D. Shapiro. 1997. Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science. 277:2002–2004.
28. Senior, R.M., G.L. Griffin, C.J. Fliszar, S.D. Shapiro, G.I. Goldberg, and H.G. Welsgus. 1991. Human 92- and 72-kilodalton type IV collagenases are elastases. J. Biol. Chem. 266:7870–7875.
29. Shi, G.-P., J.S. Munger, J.P. Meara, D.H. Rich, and H.A. Chapman. 1992. Molecular cloning and expression of human alveolar macrophage cathepsin S, an elastinolytic cysteine protease. J. Biol. Chem. 267:7258–7562.
30. Kuhn, C.I., R.J. Homer, Z. Zhu, N. Ward, R. Flavell, and J.A. Elias. 2000. Airways hyperresponsiveness and airways obstruction in transgenic mice: morphologic correlates in mice overexpressing IL-11 and IL-6. Am. J. Respir. Cell Mol. Biol. 22:289–295.
31. Lee, J.J., M.P. McGarry, S.C. Farmer, K.L. Denzler, K.A. Larson, P.E. Carrigan, I.E. Brennese, M.A. Horton, A. Haczko, E.W. Gelfand, et al. 1997. Interleukin-5 expression in the lung epithelium of transgenic mice leads to pulmonary changes pathognomonic of asthma. J. Exp. Med. 185:2143–2156.
32. Snider, G.L., J. Kleinerman, W.M. Thurlbeck, and Z.H. Bengali. 1985. The definition of emphysema: report of a National Heart, Lung, and Blood Institute, Division of Lung Diseases workshop. Am. Rev. Respir. Dis. 132:182–185.
33. Hosken, N.A., K. Shibuya, A.W. Heath, K.M. Murphy, and A. O’Garra. 1995. Human 92- and 72-kilodalton type IV collagenases are elastases. J. Biol. Chem. 266:7870–7875.
34. Ray, A., and L. Cohn. 1999. Th2 cells and GATA-3 in asthma: new insights into the regulation of airway inflammation. J. Clin. Invest. 104:1001–1006.
35. Isaacs, D., C.R.M. Bangham, and A.J. McMichael. 1987. Cell mediated cytotoxic responses to respiratory syncytial virus in infants with bronchiolitis. Lancet. 2:769–771.
36. Kemeny, D.M., B. Vyas, M. Vukmanovic-Stejic, M.J. Thomas, A. Noble, L.-C. Loh, and B.J. O’Connor. 1999. CD8+ T cell subsets and chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 160:S33–S37.
37. Lams, B.E., A.R. Sousa, P.J. Rees, and T.H. Lee. 1998. Immunopathology of the small-airway submucosa in smokers with and without chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 158:1518–1523.
38. Zheng, T., Z. Zhu, Z. Wong, R.J. Homer, B. Ma, R.J. Riese, Jr., H.A. Chapman, Jr., S.D. Shapiro, and J.A. Elias. 2000. Inducible targeting of IL-13 to the adult lung causes...
matrix metalloproteinase- and cathepsin-dependent emphysema. *J. Clin. Invest.* 106:1081–1093.

38. Minty, A., S. Asselin, A. Bensussan, D. Shire, N. Vita, A. Vyakarnam, J. Wijdenes, P. Ferrara, and D. Caput. 1997. The related cytokines interleukin-13 and interleukin-4 are distinguished by differential production and differential effects on T lymphocytes. *Eur. Cytokine Netw.* 8:203–213.

39. Liou, T.G., and E.J. Campbell. 1996. Quantum proteolysis resulting from release of single granules by human neutrophils. *J. Immunol.* 157:2624–2631.

40. Fischer, B., and J. Voynow. 2000. Neutrophil elastase induces MUC5AC messenger RNA expression by an oxidant-dependent mechanism. *Chest.* 117(Suppl. 1):317S–320S.

41. Stockley, R.A. 1994. The role of proteinases in the pathogenesis of chronic bronchitis. *Am. J. Respir. Crit. Care Med.* 150:S109–S113.

42. Hubbard, R.C., G. Fells, J. Gadek, S. Pacholok, J. Humes, and R.G. Crystal. 1991. Neutrophil accumulation in the lung in alpha-1-antitrypsin deficiency: spontaneous release of leukotriene B4 by alveolar macrophages. *J. Clin. Invest.* 88:891–897.

43. Keatings, V.M., P.D. Collins, D.M. Scott, and P.J. Barnes. 1996. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. *Am. J. Respir. Crit. Care Med.* 153:530–534.

44. Totti, N., K.T. McCusker, E.J. Campbell, G.L. Griffin, and R.M. Senior. 1984. Nicotine is chemotactic for neutrophils and enhances neutrophil responses to chemotactic peptides. *Science.* 223:169–171.

45. Stolk, J, A. Rudolphus, P. Davies, D. Oisinga, J.H. Dijkman, L. Agarwal, K.P. Keenan, D. Fletcher, and J.A. Kramps. 1992. Induction of emphysema and bronchial mucus cell hyperplasia by intratracheal instillation of lipopolysaccharide in the hamster. *J. Pathol.* 167:349–356.

46. Cohn, L., R.J. Homer, A. Marinov, J. Rankin, and K. Bottomly. 1997. Induction of airway mucus production by T helper 2 (Th2) cells: a critical role for interleukin 4 in cell recruitment but not mucus production. *J. Exp. Med.* 186:1737–1747.

47. Paludan, S.R. 2000. Synergistic action of pro-inflammatory agents: cellular and molecular aspects. *J. Leukoc. Biol.* 67:18–25.

48. Shapiro, S.D. 2000. Animal models for chronic obstructive pulmonary disease: age of klotho and marlboro mice. *Am. J. Respir. Cell Mol. Biol.* 22:4–7.

49. Graubert, T., J. Johnston, and N. Berliner. 1993. Cloning and expression of the cDNA encoding mouse neutrophil gelatinase: demonstration of coordinate secondary granule gene expression during terminal neutrophil maturation. *Blood.* 82:3192–3197.

50. Finlay, G.A., K.J. Russell, K.J. McMahon, E.M. D’arcy, J.M. Masterson, M.X. FitzGerald, C.M. O’Connor. 1997. Elevated levels of matrix metalloproteinases in bronchoalveolar lavage fluid of emphysematous patients. *Thorax.* 52:502–506.

51. Chandler, S.J., J. Cossins, J. Lury, and G. Wells. 1996. Matrix metalloelastase degrades matrix and myelin proteins and processes a tumor necrosis factor alpha fusion protein. *Biochem. Biophys. Res. Commun.* 228:421–429.

52. Ohnishi, K., M. Takagi, Y. Kurokawa, S. Satomi, and Y.T. Konttinen. 1998. Matrix metalloproteinase-mediated extracellular matrix protein degradation in human pulmonary emphysema. *Lab. Invest.* 78:1077–1087.

53. Chapman, H.A., R.J. Riese, and G.-P. Shi. 1997. Emerging roles for cysteine proteases in human biology. *Am. Rev. Physiol.* 59:63–88.

54. Takeyabu, K., T. Betsuyaku, M. Nishimura, A. Yoshioka, M. Tanino, K. Miyamoto, and Y. Kawakami. 1998. Cysteine proteinases and cystatin C in bronchoalveolar lavage fluid from subjects with subclinical emphysema. *Eur. Respir. J.* 12:1033–1039.

55. Takahashi, H., K. Ishidoh, D. Muno, A. Ohwada, T. Nukiwa, E. Komimani, and S. Kira. 1993. Cathepsin L activity is increased in alveolar macrophages and bronchoalveolar lavage fluid of smokers. *Am. Rev. Respir. Dis.* 147:1562–1568.

56. Zitnik, R.J., J. Zhang, M.A. Kashem, T. Kohno, D.E. Lyons, C.D. Wright, E. Rosen, I. Goldberg, and A.C. Hayday. 1997. The cloning and characterization of a murine secretory leukocyte protease inhibitor cDNA. *Biochem. Biophys. Res. Commun.* 232:667–697.

57. Moller, D.R., J.D. Forman, M.C. Liu, P.W. Noble, B.M. Greenlee, P. Vyas, D.A. Holden, J.M. Forrester, A. Lazarus, M. Wysocka, et al. 1996. Enhanced expression of IL-12 associated with Th1 cytokine profiles in active pulmonary sarcoidosis. *J. Immunol.* 156:4952–4960.

58. Neuringer, I.P., S.P. Wals, R.B. Mannion, S. Gabriel, and R.M. Aris. 2000. Enhanced T cell cytokine gene expression in mouse airway obliterative bronchiolitis. *Transplantation.* 69:399–405.

59. Davis, G.S., L.M. Pfeiffer, and D.R. Hemmenway. 1999. Expansion of interferon-gamma-producing lung lymphocytes in mouse silicosis. *Am. J. Respir. Cell Mol. Biol.* 20:813–824.

60. Majumdar, S., D. Li, T. Ansari, P. Pantelidis, C.M. Black, M. Giziyczki, R.M. duBois, and P.K. Jeffer. 1999. Different cytokine profiles in Cryptoencephalitis fibrosis, fibrosis of fibrosis and fibrosis associated with systemic sclerosis: a quantitative study of open lung biopsies. *Eur. Respir. J.* 14:251–257.

61. Ross, D.J., A. Moudgil, A. Bagga, M. Toyoda, A.M. Marchevsky, R.M. Kass, and S.C. Jordan. 1999. Lung allograft dysfunction correlates with gamma-interferon gene expression in bronchoalveolar lavage. *J. Heart Lung Transplant.* 18:627–638.

62. Wang, J., J. Wakeham, R. Harkness, and Z. Xing. 1999. Macrophages are a significant source of type 1 cytokines during mycobacterial infection. *J. Clin. Invest.* 103:1023–1029.

63. Helene, M., V. Lake-Bullock, J. Zhu, H. Hao, D.A. Cohen, and A.M. Kaplan. 1999. T cell independence of bleomycin-induced pulmonary fibrosis. *J. Leukoc. Biol.* 65:187–195.

64. Diaz, P.T., M.A. King, E.R. Pacht, M.D. Wevers, J.E. Gadek, H.N. Nagara, J. Drake, and T.L. Clanton. 2000. Increased susceptibility to pulmonary emphysema among HIV-seropositive smokers. *Ann. Intern. Med.* 132:369–372.

65. Podlech, J., R. Holtappels, M.F. Pahl-Seibert, H.P. Steffens, and M.J. Reddehase. 2000. Murine model of interstitial cytomegalovirus pneumonia in syngeneic bone marrow transplantation: persistence of protective pulmonary CD8+ T-cell infiltrates after clearance of acute infection. *J. Virol.* 74:7496–7507.